Highlights newsletter 2
This newsletter presents you the following key sessions:
1. Video-interview with Professor Gilles Salles about an interim analysis of the global pivotal phase II
trial of CTL019 in relapsed/refractory DLBCL
2. Extended follow-up of CheckMate 205: frequent and durable responses in patients with r/r classical Hodgkin
lymphoma treated with nivolumab
3. Addition of daratumumab to Rd or Vd improves treatment outcomes for both the standard-risk and high-risk
patients with relapsed or refractory multiple myeloma
4. Prospective H102 study: leukemic stem cell frequency combined with MRD is an important biomarker to
predict relapse in acute myeloid leukemia
5. Nearly half of PH+ CML-CP patients remain in treatment-free remission 96 weeks after discontinuing
treatment with nilotinib